You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 9,492,410


✉ Email this page to a colleague

« Back to Dashboard


Title:Methods for treatment of Parkinson's disease
Abstract: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
Inventor(s): Fariello; Ruggero (Luino, IT), Cattaneo; Carlo (Milan, IT), Salvati; Patricia (Arese, IT), Benatti; Luca (S. Maurizio al Lambro, IT)
Assignee: NEWRON PHARMACEUTICALS S.P.A. (Bresso, IT)
Filing Date:Nov 04, 2014
Application Number:14/532,925
Claims:1. A method of treating secondary and psychosocial symptoms of idiopathic Parkinson's disease comprising: administering a therapeutically effective stable dose of a single dopamine agonist; and concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule.

2. The method according to claim 1, wherein said secondary and psychosocial symptoms are selected from bradyphrenia, constipation, dementia, dysphagia, hyperhidrosis, hypersalivation, hypophonia, incontinence, micrographia, anxiety, depression, isolation and seborrhea.

3. The method according to claim 1, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered for at least 12 weeks.

4. The method according to claim 1, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered once daily.

5. The method according to claim 1, wherein safinamide is administered as the methanesulfonate salt.

6. The method according to claim 1, wherein the single dopamine agonist is selected from the group consisting of ropinirole, pramiprexole, rotigotine, bromocriptine, cabergoline, lisuride, pergolide, apomorphine, sumanirole, talipexole and dihydroergocriptine.

7. A method of limiting adverse events in a patient with idiopathic Parkinson's disease comprising: administering a therapeutically effective stable dose of a single dopamine agonist; and concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule.

8. The method according to claim 7, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered for at least 12 weeks.

9. The method according to claim 7, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered once daily.

10. The method according to claim 7, wherein safinamide is administered as the methanesulfonate salt.

11. The method according to claim 7, wherein the single dopamine agonist is selected from the group consisting of ropinirole, pramiprexole, rotigotine, bromocriptine, cabergoline, lisuride, pergolide, apomorphine, sumanirole, talipexole and dihydroergocriptine.

12. A method of treating idiopathic Parkinson's disease comprising: administering a therapeutically effective stable dose of a single dopamine agonist selected from the group consisting of bromocriptine, cabergoline, lisuride, pergolide, apomorphine, sumanirole, talipexole and dihydroergocriptine; and concurrently administering a therapeutically effective amount of safinamide, or a pharmaceutically acceptable salt thereof, on an oral daily dosage schedule.

13. The method according to claim 12, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered for at least 12 weeks.

14. The method according to claim 12, wherein safinamide, or a pharmaceutically acceptable salt thereof, is administered once daily.

15. The method according to claim 12, wherein safinamide is administered as the methanesulfonate salt.

16. The method according to claim 7, wherein the adverse events are selected from abdominal pain, abdominal pain upper, vomiting, diarrhea, somnolence, and headache.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.